BioTime, Inc. completed the acquisition of an unknown minority stake in Cell Cure Neurosciences Ltd.
January 29, 2013 at 09:30 am IST
Share
BioTime, Inc. signed an agreement to acquire unknown minority stake in Cell Cure Neurosciences Ltd. for $3.3 million in stock on November 1, 2012. BioTime will acquire 0.09 million shares of Cell Cure and issue 0.91 million shares of BioTime, Inc. As a result of the share purchase BioTime will own, directly and through wholly owned subsidiary ES Cell International Pte. Ltd. approximately 62.6% of the outstanding ordinary shares of Cell Cure Neurosciences Ltd. The transaction is subject to approval for listing of new shares. Richard S. Soroko of Lippenberger Thompson Welch Soroko acted as legal advisor to BioTime, Inc. Yael Baratz of Baratz & Co. Attorneys At Law & Notaries acted as legal advisor to Cell Cure Neurosciences Ltd.
BioTime, Inc. completed the acquisition of an unknown minority stake in Cell Cure Neurosciences Ltd on January 29, 2013.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Companyâs programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.
LINEAGE CELL THERAPEUTICS, INC. 
